Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 26, 2026.

Mast Cells, Neuroinflammation and Pain in Fibromyalgia Syndrome

Theoharis C. Theoharides, Irene Tsilioni, Mona Bawazeer

Frontiers in Cellular Neuroscience · 2019 · Review · CC BY

doi:10.3389/fncel.2019.00353

Abstract

Fibromyalgia Syndrome (FMS) is a disorder of chronic, generalized muscular pain, accompanied by sleep disturbances, fatigue and cognitive dysfunction. There is no definitive pathogenesis except for altered central pain pathways. We previously reported increased serum levels of the neuropeptides substance P (SP) and its structural analogue hemokinin-1 (HK-1) together with the pro-inflammatory cytokines IL-6 and TNF in FMS patients as compared to sedentary controls. We hypothesize that thalamic mast cells contribute to inflammation and pain, by releasing neuro-sensitizing molecules that include histamine, IL-1β, IL-6 and TNF, as well as calcitonin-gene related peptide (CGRP), HK-1 and SP. These molecules could either stimulate thalamic nociceptive neurons directly, or via stimulation of microglia in the diencephalon. As a result, inhibiting mast cell stimulation could be used as a novel approach for reducing pain and the symptoms of FMS.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 26, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Fibromyalgia Syndrome is a disorder of chronic generalized muscular pain, stiffness, generalized fatigue, sleep abnormalities, and cognitive problems assessed by the FSQ, which has about 93% sensitivity and 92% specificity. FMS affects about 5% of adults, primarily women 20–60 years of age and belongs to a family of overlapping painful conditions (Table 1) known as CSS. Central sensitization is recognized as the main mechanism involved and is characterized by allodynia, pain from an otherwise non-painful stimulus, and hyperalgesia due to an exaggerated response to a painful stimulus. The pathogenesis of FMS remains unknown and with no objective diagnostic criteria. FMS patients have reduced tolerance to pain, especially extremes of heat and cold. There is considerable evidence of altered circuity of pain networks and abnormal pain processing in FMS.

The PubMed database was searched between 1960 and 2018 using the terms fatigue, fibromyalgia, hypothalamus, inflammation, mast cells, pain and stress. Only articles in English were included.

Here we discuss how brain mast cell release of neuro-sensitizing mediators in the thalamus leads to focal inflammation and contribute to the pathogenesis of FMS.

Neurohormonal Triggers of Mast Cells Contribute to Focal Inflammation in the Diencephalon

It was recently proposed that FMS may involve localized inflammation in the hypothalamus. Elevations in pro-inflammatory chemokines/cytokines could negatively impact symptoms leading to sensitization of peripheral and central nociceptors. Increased levels of the pro-inflammatory chemokine IL-8 (CXCL8) have been reported in the serum and CSF in patients with FMS. Chemokines facilitate nociception by directly acting on chemokine receptors present along the pain pathway.

The cytokines TNF and IL-17 greatly contribute to the inflammatory response. Plasma levels of IL-17 were increased and correlated with levels of TNF in patients with FMS. CSF and serum IL-17 also positively correlated with pain and anxiety. Mast cells, themselves, can secrete IL-17; moreover, IL-6 and TGFβ from mast cells contribute to the development of Th-17 cells.

Fibromyalgia syndrome worsen by stress, which augments pain responses. Plasma concentrations of cortisol are increased in the evening, suggesting disruption of the circadian rhythm. Serum levels of CRH, which is secreted under stress, were increased in patients with FMS. CRH was also increased in the CSF of such patients and correlated with severity of pain. Physiological stress was reported to be the most common trigger in patients with systemic mastocytosis (SM) who also commonly experience FMS. We reported increased levels of CRH in the serum of one patient with indolent systemic mastocytosis. CRH can trigger human mast cells to release VEGF without histamine or tryptase. CRH also has synergistic action with NT stimulating VEGF release. As a result, there is increased vascular permeability in the skin and the blood-brain barrier (BBB). Stress also disrupts the gut-blood barrier allowing for gut microbiome-associated molecules, such as propionate to enter the brain and contribute to focal inflammation. These results have led to the conclusion that mast cells may serve as “immune gate to the brain”.

Levels of the neuropeptide SP and NGF are elevated in the CSF of FMS patients. NGF has been reported to increase nociception and hyperalgesia. The SP receptor NK-1 has been involved in the pathophysiology of pain. We reported increased serum levels of SP, its structural analogue Hemokinin-1 (HK-1) and TNF in patients with FMS. SP and NGF can stimulate mast cells. Moreover, SP induced mast cell expression of CRHR-1. Cerebrovascular mast cells were stimulated by CGRP, which is now well established to participate in the pathophysiology of headaches. In addition to neuropeptides, sex hormones can also affect mast cell reactivity. For instance, estradiol augments immune and allergic processes. In particular, we had reported expression of estrogen receptors on rodent mast cells. We also reported that 17β-estradiol further increased stimulation of mast cells by SP. Such findings may help explain why FMS is more common in women.

In addition to allergic reactions, mast cells contribute to innate immunity, autoimmunity and inflammation.

Thalamic Mast Cells Secrete Neurosensitizing Mediators

Increasing evidence supports the involvement of mast cells in FMS and comorbid disorders as well as other inflammatory and painful conditions, as well as neuroimmune interactions (Figure 1). Chronic urticaria, which involves stimulation of skin mast cells is more common in FMS. Moreover, mast cells are significantly increased in the papillary dermis of FMS patients. The chemokines monocyte chemoattractant protein-1 (MCP-1/CCL2) and eotaxin (CCL-11) are elevated in plasma of FMS patients. MCP-1 is a strong mast cell chemoattractant and also triggers mast cells in rodents. MCP-1 induced prolonged muscle hyperalgesia in rats via activation of its high-affinity receptor, CC Chemokine receptor 2 (CCR2), on the peripheral nerve terminals. Myoblasts treated with MCP-1 secreted significant amounts of the key pro-inflammatory cytokine IL-1β. C-reactive protein (CRP) is now considered a marker of chronic inflammation. CRP may be useful in the diagnostic of FMS (and depression/anxiety that often accompany FMS), even though there is no direct correlation reported.

Mast cells derive from the bone marrow and mature in response to SCF, which acts via the cell surface tyrosine kinase KIT receptor. Mast cell progenitors then migrate in all tissues. As a result, mast cell mediators can affect all organs and lead to multiple symptoms. Mast cells are found adjacent to blood vessels and nerve endings; in the brain, mast cells are located in the thalamus, hypothalamus and median eminence.

Mast cells are known to be stimulated by IgE, via activation of its unique surface receptors (FcεRI). Mast cells can also be stimulated via TLRs,. Stimulated mast cells secrete multiple vasoactive, pro-inflammatory and neuro-sensitizing molecules. Stimulation of mast cells can be augmented by the cytokine IL-33, which synergizes with SP to induce release of impressive amounts of VEGF, TNF or IL-1β. As a result, mast cells can serve as “sensors of cell danger”.

Mast cell secretory granules store many preformed pro-inflammatory and neuro-sensitizing mediators including bradykinin, histamine, TNF and tryptase. Mast cells also release de novo synthesized molecules: (a) lipid mediators (leukotrienes, prostaglandins, and PAF), (b) cytokines (IL-6, IL-13, IL-33, TNF) and (c) chemokines (CXCL8, CCL2, CCL5),. Mast cell could often release mediators selectively without histamine or tryptase. Mast cells also release IL-31, which is important in the sensation of itching and pain, in response to IgE and SP, IL-33 and specifically their combination. We reported that mast cells can release mtDNA, which is mistaken as a pathogen and stimulates inflammatory responses.

Finally, mast cells can release extracellular vesicles (exosomes) that could deliver regulatory molecules, including mtDNA and microRNAs. Such microvesicles have been implicated in brain disorders and pain disorders. We recently reported that extracellular vesicles are increased in the serum of children with ASD, contained mtDNA and stimulated cultured human microglia to secrete the pro-inflammatory molecules IL-1β and CXCL8.

Mast Cell Interactions With Microglia

Mast cells communicate with microglia. Mediators secreted from mast cells, such as histamine and tryptase, can activate microglia leading to secretion of the pro-inflammatory cytokines IL-1β, IL-6 and TNF. Microglia can also be activated by CRH secreted from mast cells. Stimulation of brain mast cells in mice led to activation of microglia, which was decreased by administration of a mast cell inhibitor.

Microglia are involved in synapse plasticity, but are responsible for innate immunity of the brain. Microglia contribute to brain inflammation and the pathogenesis of different brain disorders, especially ASD. Microglia in the thalamus have been discussed in the context of pain, especially maintaining the pain sensation even after the original painful stimulus is not present.

Conclusion

Mast cells have been implicated in headaches and pain. Activation of the mast cell-specific receptor, MRGPRX2, and its mouse analogue, Mrgprb2, mediated inflammatory mechanical and thermal hyperalgesia. Hence, mast cells are key players of neuroendocrine and painful disorders.

In this context, inhibitors of mast cells would be useful in the treatment of FMS. Natural molecules could include the flavonoids, luteolin and tetramethoxyluteolin, alone or in combination with other substances selected to reduce stress. Other natural molecules could include palmitoylethanolamide, which apparently inhibits neuro-inflammation and reduces pain.

Future Directions

Research should focus on identifying in serum of patients with FMS novel molecules that are involved in pain transmission such as bradykinin, CGRP and IL-31. Extracellular vesicles should also be isolated from the serum and CSF of FMS patients, their content identified, and their effect investigated on cultured human mast cells and microglia. Such possible interactions would serve as useful in vitro assays for the screening of potential novel treatment agents. Recent reports have also stressed the possible use of the cytokine IL-37, which is known to have anti-inflammatory actions. It would be important to explore the possible use of IL-37 isoforms in the treatment of FMS.

Author Contributions

TT, IT, and MB participated in searching the literature. TT and IT wrote or contributed to the writing of the manuscript. IT prepared the figure.

Conflict of Interest Statement

TT is the inventor of US patents No. 7,906,153 and No. 8,268,365 for the treatment of neuroinflammatory conditions. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 167

  1. 1.

    Abbadie C. (2005 ). Chemokines, chemokine receptors and pain. Trends Immunol. 26 529–534.

    Not in our library10.1016/j.it.2005.08.001

  2. 2.

    Abraham S. N. St John A. L. (2010 ). Mast cell-orchestrated immunity to pathogens. Nat. Rev. Immunol. 10 440–452.

    Not in our library10.1038/nri2782

  3. 3.

    Aguzzi A. Barres B. A. Bennett M. L. (2013 ). Microglia: scapegoat, saboteur, or something else? Science 339 156–161.

    Not in our library10.1126/science.1227901

  4. 4.
    Mast Cell-Mediated Mechanisms of Nociception · 2015
    No notice
  5. 5.

    Alvarez P. Green P. G. Levine J. D. (2014 ). Role for monocyte chemoattractant protein-1 in the induction of chronic muscle pain in the rat. Pain 155 1161–1167.

    Not in our library10.1016/j.pain.2014.03.004

  6. 6.

    Ashaari Z. Hadjzadeh M. A. Hassanzadeh G. Alizamir T. Yousefi B. Keshavarzi Z. (2018 ). The flavone luteolin improves central nervous system disorders by different mechanisms: a review. J. Mol. Neurosci. 65 491–506.

    Not in our library10.1007/s12031-018-1094-2

  7. 7.

    Banati R. B. (2002 ). Brain plasticity and microglia: is transsynaptic glial activation in the thalamus after limb denervation linked to cortical plasticity and central sensitisation? J. Physiol. Paris 96 289–299.

    Not in our library10.1016/s0928-4257(02)00018-9

  8. 8.

    Bazzichi L. Rossi A. Massimetti G. Giannaccini G. Giuliano T. De Feo F. (2007 ). Cytokine patterns in fibromyalgia and their correlation with clinical manifestations. Clin. Exp. Rheumatol. 25 225–230.

    Not in our library

  9. 9.

    Behm F. G. Gavin I. M. Karpenko O. Lindgren V. Gaitonde S. Gashkoff P. A. (2012 ). Unique immunologic patterns in fibromyalgia. BMC Clin. Pathol. 12:25.

    Not in our library10.1186/1472-6890-12-25

  10. 10.

    Blanco I. Beritze N. Arguelles M. Carcaba V. Fernandez F. Janciauskiene S. (2010 ). Abnormal overexpression of mastocytes in skin biopsies of fibromyalgia patients. Clin. Rheumatol. 29 1403–1412.

    Not in our library10.1007/s10067-010-1474-7

  11. 11.
    Sequential alteration of microglia and astrocytes in the rat thalamus following spinal nerve ligation · 2018
    Not checked
  12. 12.

    Bote M. E. Garcia J. J. Hinchado M. D. Ortega E. (2012 ). Inflammatory/stress feedback dysregulation in women with fibromyalgia. Neuroimmunomodulation 19 343–351.

    Not in our library10.1159/000341664

  13. 13.

    Bote M. E. Garcia J. J. Hinchado M. D. Ortega E. (2013 ). Fibromyalgia: anti-inflammatory and stress responses after acute moderate exercise. PLoS One 8:e74524.

    Not in our library10.1371/journal.pone.0074524

  14. 14.

    Branco J. C. Bannwarth B. Failde I. Abello C. J. Blotman F. Spaeth M. (2010 ). Prevalence of fibromyalgia: a survey in five European countries. Semin. Arthritis Rheum. 39 448–453.

    Not in our library10.1016/j.semarthrit.2008.12.003

  15. 15.

    Cao J. Papadopoulou N. Kempuraj D. Boucher W. S. Sugimoto K. Cetrulo C. L. (2005 ). Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J. Immunol. 174 7665–7675.

    Not in our library10.4049/jimmunol.174.12.7665

  16. 16.

    Carvalho L. S. Correa H. Silva G. C. Campos F. S. Baiao F. R. Ribeiro L. S. (2008 ). May genetic factors in fibromyalgia help to identify patients with differentially altered frequencies of immune cells? Clin. Exp. Immunol. 154 346–352.

    Not in our library10.1111/j.1365-2249.2008.03787.x

  17. 17.

    Cavalli G. Dinarello C. A. (2018 ). Suppression of inflammation and acquired immunity by IL-37. Immunol. Rev. 281 179–190.

    Not in our library10.1111/imr.12605

  18. 18.

    Charo I. F. Ransohoff R. M. (2006 ). The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354 610–621.

    Not in our library10.1056/nejmra052723

  19. 19.

    Chatterjea D. Martinov T. (2014 ). Mast cells: versatile gatekeepers of pain. Mol. Immunol. 63 38–44.

    Not in our library10.1016/j.molimm.2014.03.001

  20. 20.

    Clauw D. J. (2014 ). Fibromyalgia: a clinical review. JAMA 311 1547–1555.

    Not in our library10.1001/jama.2014.3266

  21. 21.

    Clauw D. J. Arnold L. M. McCarberg B. H. (2011 ). The science of fibromyalgia. Mayo Clin. Proc. 86 907–911.

    Not in our library10.4065/mcp.2011.0206

  22. 22.

    Conti P. Reale M. Barbacane R. C. Letourneau R. Theoharides T. C. (1998 ). Intramuscular injection of hrRANTES causes mast cell recruitment and increased transcription of histidine decarboxylase: lack of effects in genetically mast cell-deficient W/Wv mice. FASEB J. 12 1693–1700.

    Not in our library10.1096/fasebj.12.15.1693

  23. 23.

    Conti P. Theoharides T. C. (1994 ). Monocyte chemotactic Protein-1 (MCP-1) is active on mast cells and causes clump formation. Int. J. Immunopathol. Pharmacol. 7 149–151. 8550082

    Not in our library

  24. 24.

    Crofford L. J. Young E. A. Engleberg N. C. Korszun A. Brucksch C. B. McClure L. A. (2004 ). Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome. Brain Behav. Immun. 18 314–325.

    Not in our library10.1016/s0889-1591(04)00021-2

  25. 25.

    De Berardis D. Campanella D. Gambi F. La R. R. Carano A. Conti C. M. (2006 ). The role of C-reactive protein in mood disorders. Int. J. Immunopathol. Pharmacol. 19 721–725.

    Not in our library10.1177/039463200601900402

  26. 26.

    De Berardis D. Serroni N. Campanella D. Marini S. Rapini G. Valchera A. (2017 ). Alexithymia, suicide ideation, C-Reactive Protein, and serum lipid levels among outpatients with generalized anxiety disorder. Arch. Suicide Res. 21 100–112.

    Not in our library10.1080/13811118.2015.1004485

  27. 27.

    Desmeules J. A. Cedraschi C. Rapiti E. Baumgartner E. Finckh A. Cohen P. (2003 ). Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum. 48 1420–1429.

    Not in our library10.1002/art.10893

  28. 28.

    Donelan J. Boucher W. Papadopoulou N. Lytinas M. Papaliodis D. Theoharides T. C. (2006 ). Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. Proc. Natl. Acad. Sci. U.S.A. 103 7759–7764.

    Not in our library10.1073/pnas.0602210103

  29. 29.

    Dong H. Zhang W. Zeng X. Hu G. Zhang H. He S. (2014 ). Histamine induces upregulated expression of histamine receptors and increases release of inflammatory mediators from microglia1. Mol. Neurobiol. 49 1487–1500.

    Not in our library10.1007/s12035-014-8697-6

  30. 30.

    Dong H. Zhang X. Wang Y. Zhou X. Qian Y. Zhang S. (2017 ). Suppression of brain mast cells degranulation inhibits microglial activation and central nervous system inflammation. Mol. Neurobiol. 54 997–1007.

    Not in our library10.1007/s12035-016-9720-x

  31. 31.
    Altered glial marker expression in autistic post-mortem prefrontal cortex and cerebellum · 2014
    No notice
  32. 32.

    Edvinsson L. (2018 ). The CGRP pathway in migraine as a viable target for therapies. Headache 58(Suppl. 1), 33–47.

    Not in our library10.1111/head.13305

  33. 33.

    Edvinsson L. Owman C. Sjöberg N. O. (1976 ). Autonomic nerves, mast cells and amine receptors in human brain vessels. A histochemical and pharmacological study. Brain Res. 115 377–393.

    Not in our library10.1016/0006-8993(76)90356-5

  34. 34.

    Enoksson M. Lyberg K. Moller-Westerberg C. Fallon P. G. Nilsson G. Lunderius-Andersson C. (2011 ). Mast cells as sensors of cell injury through IL-33 recognition. J. Immunol. 186 2523–2528.

    Not in our library10.4049/jimmunol.1003383

  35. 35.

    Esposito P. Chandler N. Kandere-Grzybowska K. Basu S. Jacobson S. Connolly R. (2002 ). Corticotropin-releasing hormone (CRH) and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. J. Pharmacol. Exp. Ther. 303 1061–1066.

    Not in our library10.1124/jpet.102.038497

  36. 36.

    Faden A. I. Wu J. Stoica B. A. Loane D. J. (2016 ). Progressive inflammation-mediated neurodegeneration after traumatic brain or spinal cord injury. Br. J. Pharmacol. 173 681–691.

    Not in our library10.1111/bph.13179

  37. 37.

    Ferrari R. Russell A. S. (2013 ). A questionnaire using the modified 2010 American College of rheumatology criteria for fibromyalgia: specificity and sensitivity in clinical practice. J. Rheumatol. 40 1590–1595.

    Not in our library10.3899/jrheum.130367

  38. 38.

    Flodin P. D. Martinsen S. Lofgren M. Bileviciute-Ljungar I. Kosek E. Fransson P. (2014 ). Fibromyalgia is associated with decreased connectivity between pain- and sensorimotor brain areas. Brain Connect. 4 587–594.

    Not in our library10.1089/brain.2014.0274

  39. 39.

    Fux M. Pecaric-Petkovic T. Odermatt A. Hausmann O. V. Lorentz A. Bischoff S. C. (2014 ). IL-33 is a mediator rather than a trigger of the acute allergic response in humans. Allergy 69 216–222.

    Not in our library10.1111/all.12309

  40. 40.

    Galli S. J. Borregaard N. Wynn T. A. (2011 ). Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat. Immunol. 12 1035–1044.

    Not in our library10.1038/ni.2109

  41. 41.

    Galli S. J. Tsai M. (2008 ). Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis. J. Dermatol. Sci. 49 7–19.

    Not in our library10.1016/j.jdermsci.2007.09.009

  42. 42.

    Galli S. J. Tsai M. Piliponsky A. M. (2008 ). The development of allergic inflammation. Nature 454 445–454.

    Not in our library10.1038/nature07204

  43. 43.

    Garden G. A. Campbell B. M. (2016 ). Glial biomarkers in human central nervous system disease. Glia 64 1755–1771.

    Not in our library10.1002/glia.22998

  44. 44.

    Geenen R. Jacobs J. W. Bijlsma J. W. (2002 ). Evaluation and management of endocrine dysfunction in fibromyalgia. Rheum. Dis. Clin. North Am. 28 389–404.

    Not in our library10.1016/s0889-857x(01)00009-6

  45. 45.

    Giovengo S. L. Russell I. J. Larson A. A. (1999 ). Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J. Rheumatol. 26 1564–1569.

    Not in our library

  46. 46.

    Green D. P. Limjunyawong N. Gour N. Pundir P. Dong X. (2019 ). A Mast-Cell-Specific receptor mediates neurogenic inflammation and pain. Neuron 101 412–420.

    Not in our library10.1016/j.neuron.2019.01.012

  47. 47.

    Greenwood-Van M. B. Mohammadi E. Tyler K. Pietra C. Bee L. A. Dickenson A. (2014 ). Synergistic effect of 5-hydroxytryptamine 3 and neurokinin 1 receptor antagonism in rodent models of somatic and visceral pain. J. Pharmacol. Exp. Ther. 351 146–152.

    Not in our library10.1124/jpet.114.216028

  48. 48.

    Griffin G. K. Newton G. Tarrio M. L. Bu D. X. Maganto-Garcia E. Azcutia V. (2012 ). IL-17 and TNF-alpha sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. J. Immunol. 188 6287–6299.

    Not in our library10.4049/jimmunol.1200385

  49. 49.

    Groh J. Martini R. (2017 ). Neuroinflammation as modifier of genetically caused neurological disorders of the central nervous system: understanding pathogenesis and chances for treatment. Glia 65 1407–1422.

    Not in our library10.1002/glia.23162

  50. 50.

    Gupta K. Harvima I. T. (2018 ). Mast cell-neural interactions contribute to pain and itch. Immunol. Rev. 282 168–187.

    Not in our library10.1111/imr.12622

  51. 51.
    Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism · 2014
    No notice
  52. 52.

    Hagberg H. Gressens P. Mallard C. (2012 ). Inflammation during fetal and neonatal life: implications for neurologic and neuropsychiatric disease in children and adults. Ann. Neurol. 71 444–457.

    Not in our library10.1002/ana.22620

  53. 53.

    Hansson E. (2010 ). Long-term pain, neuroinflammation and glial activation. Scand. J. Pain 1 67–72.

    Not in our library10.1016/j.sjpain.2010.01.002

  54. 54.

    Harvima I. T. Levi-Schaffer F. Draber P. Friedman S. Polakovicova I. Gibbs B. F. (2014 ). Molecular targets on mast cells and basophils for novel therapies. J. Allergy Clin. Immunol. 134 530–544.

    Not in our library10.1016/j.jaci.2014.03.007

  55. 55.

    Hauser W. Sarzi-Puttini P. Fitzcharles M. A. (2019 ). Fibromyalgia syndrome: under-, over- and misdiagnosis. Clin. Exp. Rheumatol. 37(Suppl. 116), 90–97.

    Not in our library

  56. 56.

    Heron A. Dubayle D. (2013 ). A focus on mast cells and pain. J. Neuroimmunol. 264 1–7.

    Not in our library10.1016/j.jneuroim.2013.09.018

  57. 57.

    Hornig M. Montoya J. G. Klimas N. G. Levine S. Felsenstein D. Bateman L. (2015 ). Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Sci. Adv. 1:e1400121.

    Not in our library10.1126/sciadv.1400121

  58. 58.

    Hox V. Desai A. Bandara G. Gilfillan A. M. Metcalfe D. D. Olivera A. (2015 ). Estrogen increases the severity of anaphylaxis in female mice through enhanced endothelial nitric oxide synthase expression and nitric oxide production. J. Allergy Clin. Immunol. 135 729–736.

    Not in our library10.1016/j.jaci.2014.11.003

  59. 59.

    Impellizzeri D. Di P. R. Cordaro M. Gugliandolo E. Casili G. Morittu V. M. (2016 ). Adelmidrol, a palmitoylethanolamide analogue, as a new pharmacological treatment for the management of acute and chronic inflammation. Biochem. Pharmacol. 119 27–41.

    Not in our library10.1016/j.bcp.2016.09.001

  60. 60.

    Jennings S. Russell N. Jennings B. Slee V. Sterling L. Castells M. (2014 ). The mastocytosis society survey on mast cell disorders: patient experiences and perceptions. J. Allergy Clin. Immunol. Pract. 2 70–76.

    Not in our library10.1016/j.jaip.2013.09.004

  61. 61.
    Patients with Fibromyalgia Display Less Functional Connectivity in the Brain's Pain Inhibitory Network · 2012
    No notice
  62. 62.

    Jiang N. M. Cowan M. Moonah S. N. Petri W. A. Jr. (2018 ). The impact of systemic inflammation on neurodevelopment. Trends Mol. Med. 24 794–804.

    Not in our library10.1016/j.molmed.2018.06.008

  63. 63.

    Kadetoff D. Lampa J. Westman M. Andersson M. Kosek E. (2012 ). Evidence of central inflammation in fibromyalgia-increased cerebrospinal fluid interleukin-8 levels. J. Neuroimmunol. 242 33–38.

    Not in our library10.1016/j.jneuroim.2011.10.013

  64. 64.

    Kawikova I. Askenase P. W. (2014 ). Diagnostic and therapeutic potentials of exosomes in CNS diseases. Brain Res. 1617 63–71.

    Not in our library10.1016/j.brainres.2014.09.070

  65. 65.

    Kempuraj D. Papadopoulou N. G. Lytinas M. Huang M. Kandere-Grzybowska K. Madhappan B. (2004 ). Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. Endocrinology 145 43–48.

    Not in our library10.1210/en.2003-0805

  66. 66.

    Kempuraj D. Tagen M. Iliopoulou B. P. Clemons A. Vasiadi M. Boucher W. (2008 ). Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell dependent stimulation of Jurkat T cells. Br. J. Pharmacol. 155 1076–1084.

    Not in our library10.1038/bjp.2008.356

  67. 67.

    Kenna T. J. Brown M. A. (2013 ). The role of IL-17-secreting mast cells in inflammatory joint disease. Nat. Rev. Rheumatol. 9 375–379.

    Not in our library10.1038/nrrheum.2012.205

  68. 68.

    Koutsouras G. W. Ramos R. L. Martinez L. R. (2017 ). Role of microglia in fungal infections of the central nervous system. Virulence 8 705–718.

    Not in our library10.1080/21505594.2016.1261789

  69. 69.

    Kovats S. (2015 ). Estrogen receptors regulate innate immune cells and signaling pathways. Cell Immunol. 294 63–69.

    Not in our library10.1016/j.cellimm.2015.01.018

  70. 70.

    Lambracht-Hall M. Dimitriadou V. Theoharides T. C. (1990 ). Migration of mast cells in the developing rat brain. Dev. Brain Res. 56 151–159.

    Not in our library10.1016/0165-3806(90)90077-c

  71. 71.

    Levi-Montalcini R. (1987 ). The nerve growth factor 35 years later. Science 237 1154–1162.

    Not in our library10.1126/science.3306916

  72. 72.

    Liu Y. Ho R. C. Mak A. (2012 ). The role of interleukin (IL)-17 in anxiety and depression of patients with rheumatoid arthritis. Int. J. Rheum. Dis. 15 183–187.

    Not in our library10.1111/j.1756-185x.2011.01673.x

  73. 73.

    Lucas H. J. Brauch C. M. Settas L. Theoharides T. C. (2006 ). Fibromyalgia–new concepts of pathogenesis and treatment. Int. J. Immunopathol. Pharmacol. 19 5–10.

    Not in our library

  74. 74.

    Maren S. (2017 ). Synapse-Specific encoding of fear memory in the amygdala. Neuron 95 988–990.

    Not in our library10.1016/j.neuron.2017.08.020

  75. 75.

    Mastrangelo F. Frydas I. Ronconi G. Kritas S. K. Tettamanti L. Caraffa A. (2018 ). Low-grade chronic inflammation mediated by mast cells in fibromyalgia: role of IL-37. J. Biol. Regul. Homeost Agents 32 195–198.

    Not in our library

  76. 76.

    McBeth J. Mulvey M. R. (2012 ). Fibromyalgia: mechanisms and potential impact of the ACR 2010 classification criteria. Nat. Rev. Rheumatol. 8 108–116.

    Not in our library10.1038/nrrheum.2011.216

  77. 77.

    McLean S. A. Williams D. A. Stein P. K. Harris R. E. Lyden A. K. Whalen G. (2006 ). Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia. Neuropsychopharmacology 31 2776–2782.

    Not in our library10.1038/sj.npp.1301200

  78. 78.

    McNeil B. D. Pundir P. Meeker S. Han L. Undem B. J. Kulka M. (2015 ). Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature 519 237–241.

    Not in our library10.1038/nature14022

  79. 79.

    Meng X. Zhang Y. Lao L. Saito R. Li A. Backman C. M. (2013 ). Spinal interleukin-17 promotes thermal hyperalgesia and NMDA NR1 phosphorylation in an inflammatory pain rat model. Pain 154 294–305.

    Not in our library10.1016/j.pain.2012.10.022

  80. 80.

    Minerbi A. Gonzalez E. Brereton N. J. B. Anjarkouchian A. Dewar K. Fitzcharles M. A. (2019 ). Altered microbiome composition in individuals with fibromyalgia. Pain [Epub ahead of print].

    Not in our library10.1097/j.pain.0000000000001640

  81. 81.

    Morgan J. T. Chana G. Pardo C. A. Achim C. Semendeferi K. Buckwalter J. (2010 ). Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol. Psychiatry 68 368–376.

    Not in our library10.1016/j.biopsych.2010.05.024

  82. 82.

    Mukai K. Tsai M. Saito H. Galli S. J. (2018 ). Mast cells as sources of cytokines, chemokines, and growth factors. Immunol. Rev. 282 121–150.

    Not in our library10.1111/imr.12634

  83. 83.

    Nakae S. Suto H. Kakurai M. Sedgwick J. D. Tsai M. Galli S. J. (2005 ). Mast cells enhance T cell activation: importance of mast cell-derived TNF. Proc. Natl. Acad. Sci. U.S.A. 102 6467–6472.

    Not in our library10.1073/pnas.0501912102

  84. 84.

    Nakagawa Y. Chiba K. (2016 ). Involvement of neuroinflammation during brain development in social cognitive deficits in autism spectrum disorder and schizophrenia. J. Pharmacol. Exp. Ther. 358 504–515.

    Not in our library10.1124/jpet.116.234476

  85. 85.

    Nugraha B. Korallus C. Kielstein H. Gutenbrunner C. (2013 ). CD3+CD56+natural killer T cells in fibromyalgia syndrome patients: association with the intensity of depression. Clin. Exp. Rheumatol. 31 S9–S15.

    Not in our library

  86. 86.

    Olszewski M. B. Groot A. J. Dastych J. Knol E. F. (2007 ). TNF trafficking to human mast cell granules: mature chain-dependent endocytosis. J. Immunol. 178 5701–5709.

    Not in our library10.4049/jimmunol.178.9.5701

  87. 87.

    Orsolini L. Sarchione F. Vellante F. Fornaro M. Matarazzo I. Martinotti G. (2018 ). Protein-C reactive as biomarker predictor of schizophrenia phases of illness? A systematic review. Curr. Neuropharmacol. 16 583–606.

    Not in our library10.2174/1570159x16666180119144538

  88. 88.

    Ottosson A. Edvinsson L. (1997 ). Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide. Cephalalgia 17 166–174.

    Not in our library10.1046/j.1468-2982.1997.1703166.x

  89. 89.

    Pang X. Cotreau-Bibbo M. M. Sant G. R. Theoharides T. C. (1995 ). Bladder mast cell expression of high affinity estrogen receptors in patients with interstitial cystitis. Br. J. Urol. 75 154–161.

    Not in our library10.1111/j.1464-410x.1995.tb07303.x

  90. 90.

    Pennisi M. Crupi R. Di P. R. Ontario M. L. Bella R. Calabrese E. J. (2017 ). Inflammasomes, hormesis, and antioxidants in neuroinflammation: role of NRLP3 in Alzheimer disease. J. Neurosci. Res. 95 1360–1372.

    Not in our library10.1002/jnr.23986

  91. 91.

    Pernambuco A. P. Schetino L. P. Alvim C. C. Murad C. M. Viana R. S. Carvalho L. S. (2013 ). Increased levels of IL-17A in patients with fibromyalgia. Clin. Exp. Rheumatol. 31 S60–S63.

    Not in our library

  92. 92.

    Petra A. I. Tsilioni I. Taracanova A. Katsarou-Katsari A. Theoharides T. C. (2018 ). Interleukin 33 and interleukin 4 regulate interleukin 31 gene expression and secretion from human laboratory of allergic diseases 2 mast cells stimulated by substance P and/or immunoglobulin E. Allergy Asthma Proc. 39 153–160.

    Not in our library10.2500/aap.2018.38.4105

  93. 93.

    Pollack S. (2014 ). Mast cells in fibromyalgia. Clin. Exp. Rheumatol. 33(1 Suppl. 88):S140.

    Not in our library

  94. 94.

    Rafiee Z. A. Falahatian M. Alsahebfosoul F. (2018 ). Serum levels of histamine and diamine oxidase in multiple sclerosis. Am. J. Clin. Exp. Immunol. 7 100–105.

    Not in our library

  95. 95.

    Ransohoff R. M. Brown M. A. (2012 ). Innate immunity in the central nervous system. J. Clin. Invest. 122 1164–1171.

    Not in our library10.1172/jci58644

  96. 96.
    The Lifespan and Turnover of Microglia in the Human Brain · 2017
    No notice
  97. 97.

    Reus G. Z. Fries G. R. Stertz L. Badawy M. Passos I. C. Barichello T. (2015 ). The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience 300 141–154.

    Not in our library10.1016/j.neuroscience.2015.05.018

  98. 98.

    Reynier-Rebuffel A.-M. Mathiau P. Callebert J. Dimitriadou V. Farjaudon N. Kacem K. (1994 ). Substance P, calcitonin gene-related peptide, and capsaicin release serotonin from cerebrovascular mast cells. Am. J. Physiol. Regul. Integr. Comp. Physiol. 267 R1421–R1429.

    Not in our library10.1152/ajpregu.1994.267.5.r1421

  99. 99.

    Ribatti D. (2015 ). The crucial role of mast cells in blood-brain barrier alterations. Exp. Cell Res. 338 119–125.

    Not in our library10.1016/j.yexcr.2015.05.013

  100. 100.

    Rivera J. Fierro N. A. Olivera A. Suzuki R. (2008 ). New insights on mast cell activation via the high affinity receptor for IgE. Adv. Immunol. 98 85–120.

    Not in our library10.1016/s0065-2776(08)00403-3

  101. 101.

    Rodriguez-Pinto I. Agmon-Levin N. Howard A. Shoenfeld Y. (2014 ). Fibromyalgia and cytokines. Immunol. Lett. 161 200–203.

    Not in our library10.1016/j.imlet.2014.01.009

  102. 102.

    Romero-Sanchez C. Jaimes D. A. Londono J. De Avila J. Castellanos J. E. Bello J. M. (2011 ). Association between Th-17 cytokine profile and clinical features in patients with spondyloarthritis. Clin. Exp. Rheumatol. 29 828–834.

    Not in our library

  103. 103.

    Ross R. L. Jones K. D. Bennett R. M. Ward R. L. Druker B. J. Wood L. J. (2010 ). Preliminary evidence of increased pain and elevated cytokines in fibromyalgia patients with defective growth hormone response to exercise. Open Immunol. J. 3 9–18.

    Not in our library10.2174/1874226201003010009

  104. 104.

    Rottem M. Mekori Y. A. (2005 ). Mast cells and autoimmunity. Autoimmun. Rev. 4 21–27.

    Not in our library10.1016/j.autrev.2004.05.001

  105. 105.

    Russell I. J. (1998 ). Advances in fibromyalgia: possible role for central neurochemicals. Am. J. Med. Sci. 315 377–384.

    Not in our library10.1016/s0002-9629(15)40355-6

  106. 106.

    Russell I. J. Larson A. A. (2009 ). Neurophysiopathogenesis of fibromyalgia syndrome: a unified hypothesis. Rheum. Dis. Clin. North Am. 35 421–435.

    Not in our library10.1016/j.rdc.2009.06.005

  107. 107.

    Saghaei E. Abbaszadeh F. Naseri K. Ghorbanpoor S. Afhami M. Haeri A. (2013 ). Estradiol attenuates spinal cord injury-induced pain by suppressing microglial activation in thalamic VPL nuclei of rats. Neurosci. Res. 75 316–323.

    Not in our library10.1016/j.neures.2013.01.010

  108. 108.

    Schmidt-Wilcke T. Clauw D. J. (2011 ). Fibromyalgia: from pathophysiology to therapy. Nat. Rev. Rheumatol. 7 518–527.

    Not in our library10.1038/nrrheum.2011.98

  109. 109.

    Scholzen T. E. Steinhoff M. Bonaccorsi P. Klein R. Amadesi S. Geppetti P. (2001 ). Neutral endopeptidase terminates substance P-induced inflammation in allergic contact dermatitis. J. Immunol. 166 1285–1291.

    Not in our library10.4049/jimmunol.166.2.1285

  110. 110.

    Schweiger V. Martini A. Bellamoli P. Donadello K. Schievano C. Del B. G. (2019 ). Ultramicronized palmitoylethanolamide (um-PEA) as add-on treatment in fibromyalgia syndrome (FMS): retrospective observational study on 407 patients. CNS Neurol. Disord. Drug Targets [Epub ahead of print].

    Not in our library10.2174/1871527318666190227205359

  111. 111.

    Shemer A. Erny D. Jung S. Prinz M. (2015 ). Microglia plasticity during health and disease: an immunological perspective. Trends Immunol. 36 614–624.

    Not in our library10.1016/j.it.2015.08.003

  112. 112.

    Silva-Freire N. Mayado A. Teodosio C. Jara-Acevedo M. Varez-Twose I. Matito A. (2019 ). Bone marrow mast cell antibody-targetable cell surface protein expression profiles in systemic mastocytosis. Int. J. Mol. Sci. 20:E552.

    Not in our library10.3390/ijms20030552

  113. 113.

    Skaper S. D. Facci L. Barbierato M. Zusso M. Bruschetta G. Impellizzeri D. (2015 ). N-Palmitoylethanolamine and neuroinflammation: a novel therapeutic strategy of resolution. Mol. Neurobiol. 52 1034–1042.

    Not in our library10.1007/s12035-015-9253-8

  114. 114.

    Skaper S. D. Facci L. Fusco M. la Valle M. F. Zusso M. Costa B. (2014a ). Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology 22 79–94.

    Not in our library10.1007/s10787-013-0191-7

  115. 115.

    Skaper S. D. Facci L. Giusti P. (2014b ). Neuroinflammation, microglia and mast cells in the pathophysiology of neurocognitive disorders: a review. CNS Neurol. Disord. Drug Targets 13 1654–1666.

    Not in our library10.2174/1871527313666141130224206

  116. 116.

    Skaper S. D. Facci L. Giusti P. (2013 ). Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. Mol. Neurobiol. 48 340–352.

    Not in our library10.1007/s12035-013-8487-6

  117. 117.

    Skaper S. D. Facci L. Zusso M. Giusti P. (2017 ). Neuroinflammation, mast cells, and glia: dangerous liaisons. Neuroscientist 23 478–498.

    Not in our library10.1177/1073858416687249

  118. 118.

    Skaper S. D. Giusti P. Facci L. (2012 ). Microglia and mast cells: two tracks on the road to neuroinflammation. FASEB J. 26 3103–3117.

    Not in our library10.1096/fj.11-197194

  119. 119.

    Skokos D. Botros H. G. Demeure C. Morin J. Peronet R. Birkenmeier G. (2003 ). Mast cell-derived exosomes induce phenotypic and functional maturation of dendritic cells and elicit specific immune responses in vivo. J. Immunol. 170 3037–3045.

    Not in our library10.4049/jimmunol.170.6.3037

  120. 120.

    Skokos D. Goubran-Botros H. Roa M. Mecheri S. (2002 ). Immunoregulatory properties of mast cell-derived exosomes. Mol. Immunol. 38 1359–1362.

    Not in our library10.1016/s0161-5890(02)00088-3

  121. 121.

    Staud R. (2011 ). Brain imaging in fibromyalgia syndrome. Clin. Exp. Rheumatol. 29 S109–S117.

    Not in our library

  122. 122.

    Staud R. Vierck C. J. Cannon R. L. Mauderli A. P. Price D. D. (2001 ). Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 91 165–175.

    Not in our library10.1016/s0304-3959(00)00432-2

  123. 123.

    Suzuki K. Sugihara G. Ouchi Y. Nakamura K. Futatsubashi M. Takebayashi K. (2013 ). Microglial activation in young adults with autism spectrum disorder. JAMA Psychiatry 70 49–58.

    Not in our library10.1001/jamapsychiatry.2013.272

  124. 124.
    Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy · 2014
    No notice
  125. 125.

    Taracanova A. Alevizos M. Karagkouni A. Weng Z. Norwitz E. Conti P. (2017 ). SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors. Proc. Natl. Acad. Sci. U.S.A. 114 E4002–E4009.

    Not in our library10.1073/pnas.1524845114

  126. 126.

    Taracanova A. Tsilioni I. Conti P. Norwitz E. R. Leeman S. E. Theoharides T. C. (2018 ). Substance P and IL-33 administered together stimulate a marked secretion of IL-1beta from human mast cells, inhibited by methoxyluteolin. Proc. Natl. Acad. Sci. U.S.A 115 E9381–E9390.

    Not in our library10.1073/pnas.1810133115

  127. 127.

    Theoharides T. C. (1983 ). Mast cells and migraines. Perspect. Biol. Med. 26 672–675.

    Not in our library10.1353/pbm.1983.0028

  128. 128.

    Theoharides T. C. (1990 ). Mast cells: the immune gate to the brain. Life Sci. 46 607–617.

    Not in our library10.1016/0024-3205(90)90129-f

  129. 129.

    Theoharides T. C. (1996 ). Mast cell: a neuroimmunoendocrine master player. Int. J. Tissue React. 18 1–21.

    Not in our library

  130. 130.

    Theoharides T. C. (2013 ). Atopic conditions in search of pathogenesis and therapy. Clin. Ther. 35 544–547.

    Not in our library10.1016/j.clinthera.2013.04.002

  131. 131.

    Theoharides T. C. (2017 ). Neuroendocrinology of mast cells: challenges and controversies. Exp. Dermatol. 26 751–759.

    Not in our library10.1111/exd.13288

  132. 132.

    Theoharides T. C. Alysandratos K. D. Angelidou A. Delivanis D. A. Sismanopoulos N. Zhang B. (2010a ). Mast cells and inflammation. Biochim. Biophys. Acta 1822 21–33.

    Not in our library10.1016/j.bbadis.2010.12.014

  133. 133.

    Theoharides T. C. Zhang B. Kempuraj D. Tagen M. Vasiadi M. Angelidou A. (2010b ). IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc. Natl. Acad. Sci. U.S.A. 107 4448–4453.

    Not in our library10.1073/pnas.1000803107

  134. 134.

    Theoharides T. C. Dimitriadou V. Letourneau R. J. Rozniecki J. J. Vliagoftis H. Boucher W. S. (1993 ). Synergistic action of estradiol and myelin basic protein on mast cell secretion and brain demyelination: changes resembling early stages of demyelination. Neuroscience 57 861–871.

    Not in our library10.1016/0306-4522(93)90030-j

  135. 135.

    Theoharides T. C. Donelan J. Kandere-Grzybowska K. Konstantinidou A. (2005 ). The role of mast cells in migraine pathophysiology. Brain Res. Brain Res. Rev. 49 65–76.

    Not in our library10.1016/j.brainresrev.2004.11.006

  136. 136.

    Theoharides T. C. Kavalioti M. (2018 ). Stress, inflammation and natural treatments. J. Biol. Regul. Homeost Agents 32 1345–1347.

    Not in our library

  137. 137.

    Theoharides T. C. Kempuraj D. Tagen M. Conti P. Kalogeromitros D. (2007 ). Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol. Rev. 217 65–78.

    Not in our library10.1111/j.1600-065x.2007.00519.x

  138. 138.

    Theoharides T. C. Konstantinidou A. (2007 ). Corticotropin-releasing hormone and the blood-brain-barrier. Front. Biosci. 12:1615–1628.

    Not in our library10.2741/2174

  139. 139.

    Theoharides T. C. Letourneau R. Patra P. Hesse L. Pang X. Boucher W. (1999 ). Stress-induced rat intestinal mast cell intragranular activation and inhibitory effect of sulfated proteoglycans. Dig. Dis. Sci. 44 87S–93S.

    Not in our library

  140. 140.

    Theoharides T. C. Petra A. I. Stewart J. M. Tsilioni I. Panagiotidou S. Akin C. (2014 ). High serum corticotropin-releasing hormone (CRH) and bone marrow mast cell CRH receptor expression in a mastocytosis patient. J. Allergy Clin. Immunol. 134 1197–1199.

    Not in our library10.1016/j.jaci.2014.05.023

  141. 141.

    Theoharides T. C. Petra A. I. Taracanova A. Panagiotidou S. Conti P. (2015a ). Targeting IL-33 in autoimmunity and inflammation. J. Pharmacol. Exp. Ther. 354 24–31.

    Not in our library10.1124/jpet.114.222505

  142. 142.

    Theoharides T. C. Stewart J. M. Hatziagelaki E. Kolaitis G. (2015b ). Brain “fog,” inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin. Front. Neurosci. 9:225.

    Not in our library10.3389/fnins.2015.00225

  143. 143.

    Theoharides T. C. Tsilioni I. Arbetman L. Panagiotidou S. Stewart J. M. Gleason R. M. (2015c ). Fibromyalgia, a syndrome in search of pathogenesis and therapy. J. Pharmacol. Exp. Ther. 355 255–263.

    Not in our library10.1124/jpet.115.227298

  144. 144.

    Theoharides T. C. Valent P. Akin C. (2015d ). Mast cells, mastocytosis, and related disorders. N. Engl. J. Med. 373 163–172.

    Not in our library10.1056/nejmra1409760

  145. 145.

    Theoharides T. C. Stewart J. M. Tsilioni I. (2017 ). Tolerability and benefit of a tetramethoxyluteolin-containing skin lotion. Int. J. Immunopathol. Pharmacol. 30 146–151.

    Not in our library10.1177/0394632017707610

  146. 146.

    Theoharides T. C. Tsilioni I. (2018 ). Tetramethoxyluteolin for the treatment of neurodegenerative diseases. Curr. Top. Med. Chem. 18 1872–1882.

    Not in our library10.2174/1568026617666181119154247

  147. 147.

    Theoharides T. C. Tsilioni I. Ren H. (2019 ). Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders? Expert. Rev. Clin. Immunol. 15 639–656.

    Not in our library10.1080/1744666x.2019.1596800

  148. 148.

    Thonhoff J. R. Simpson E. P. Appel S. H. (2018 ). Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis. Curr. Opin. Neurol. 31 635–639.

    Not in our library10.1097/wco.0000000000000599

  149. 149.

    Torresani C. Bellafiore S. De Panfilis G. (2009 ). Chronic urticaria is usually associated with fibromyalgia syndrome. Acta Derm. Venereol. 89 389–392.

    Not in our library10.2340/00015555-0653

  150. 150.

    Tsilioni I. Panagiotidou S. Theoharides T. C. (2014 ). Exosomes in neurologic and psychiatric disorders. Clin. Ther. 36 882–888.

    Not in our library10.1016/j.clinthera.2014.05.005

  151. 151.

    Tsilioni I. Russell I. J. Stewart J. M. Gleason R. M. Theoharides T. C. (2016 ). Neuropeptides CRH, SP, HK-1, and inflammatory cytokines IL-6 and TNF are increased in serum of patients with fibromyalgia syndrome, implicating mast cells. J. Pharmacol. Exp. Ther. 356 664–672.

    Not in our library10.1124/jpet.115.230060

  152. 152.
    Extracellular vesicles are increased in the serum of children with autism spectrum disorder, contain mitochondrial DNA, and stimulate human microglia to secrete IL-1β · 2018
    No notice
  153. 153.
    Systematic review with meta-analysis: cytokines in fibromyalgia syndrome · 2011
    No notice
  154. 154.

    Vargas D. L. Nascimbene C. Krishnan C. Zimmerman A. W. Pardo C. A. (2005 ). Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann. Neurol. 57 67–81.

    Not in our library10.1002/ana.20315

  155. 155.

    Wallon C. Yang P. Keita A. V. Ericson A. C. McKay D. M. Sherman P. M. (2008 ). Corticotropin releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. Gut 57 50–58.

    Not in our library10.1136/gut.2006.117549

  156. 156.

    Wang W. Ji P. Riopelle R. J. Dow K. E. (2002 ). Functional expression of corticotropin-releasing hormone (CRH) receptor 1 in cultured rat microglia. J. Neurochem. 80 287–294.

    Not in our library10.1046/j.0022-3042.2001.00687.x

  157. 157.

    Wolfe F. Walitt B. (2013 ). Culture, science and the changing nature of fibromyalgia. Nat. Rev. Rheumatol. 9 751–755.

    Not in our library10.1038/nrrheum.2013.96

  158. 158.

    Woodman I. (2013 ). Fibromyalgia: fibromyalgia-all in the brain? Nat. Rev. Rheumatol. 9:565.

    Not in our library10.1038/nrrheum.2013.137

  159. 159.

    Woolf C. J. (2011 ). Central sensitization: implications for the diagnosis and treatment of pain. Pain 152 S2–S15.

    Not in our library10.1016/j.pain.2010.09.030

  160. 160.

    Wu Y. Dissing-Olesen L. MacVicar B. A. Stevens B. (2015 ). Microglia: dynamic mediators of synapse development and plasticity. Trends Immunol. 36 605–613.

    Not in our library10.1016/j.it.2015.08.008

  161. 161.

    Xanthos D. N. Gaderer S. Drdla R. Nuro E. Abramova A. Ellmeier W. (2011 ). Central nervous system mast cells in peripheral inflammatory nociception. Mol. Pain 7:42.

    Not in our library10.1186/1744-8069-7-42

  162. 162.

    Yunus M. B. (2007 ). Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin. Arthritis Rheum. 36 339–356.

    Not in our library10.1016/j.semarthrit.2006.12.009

  163. 163.

    Zhang B. Asadi S. Weng Z. Sismanopoulos N. Theoharides T. C. (2012 ). Stimulated human mast cells secrete mitochondrial components that have autocrine and paracrine inflammatory actions. PLoS One 7:e49767.

    Not in our library10.1371/journal.pone.0049767

  164. 164.

    Zhang S. Zeng X. Yang H. Hu G. He S. (2012 ). Mast cell tryptase induces microglia activation via protease-activated receptor 2 signaling. Cell Physiol. Biochem. 29 931–940.

    Not in our library10.1159/000171029

  165. 165.

    Zhang Q. Raoof M. Chen Y. Sumi Y. Sursal T. Junger W. (2010 ). Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464 104–107.

    Not in our library10.1038/nature08780

  166. 166.

    Zhang X. Wang Y. Dong H. Xu Y. Zhang S. (2016 ). Induction of microglial activation by mediators released from mast cells. Cell Physiol. Biochem. 38 1520–1531.

    Not in our library10.1159/000443093

  167. 167.

    Zhang Z. Cherryholmes G. Mao A. Marek C. Longmate J. Kalos M. (2008 ). High plasma levels of MCP-1 and eotaxin provide evidence for an immunological basis of fibromyalgia. Exp. Biol. Med. 233 1171–1180.

    Not in our library10.3181/0712-rm-328

Cited by papers we hold 1

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.